The MATCH-B study
The Management of Chronic Hepatitis B in Africa (MATCH-B) study is an important longitudinal study following all participants with chronic hepatitis B previously enrolled in the WATCH study in Gambia and Senegal. The study is currently funded by the MRC UK and Gilead US company.
The main objectives of this study are to assess the rate of liver disease progression of chronic hepatitis B in the African environment and develop simplified algorithms to diagnose, treat and monitor HBV-infected patients in resource-limited African settings.
In the observation cohort (untreated patients): we will determine whether patients who did not require treatment will remain so without progression of liver disease. In the treatment cohort (patients under antiviral therapy since 2012 or 2013): we will assess the clinical effectiveness of nucleotide analogue therapy in West African patients. All untreated patients are reinvited for one complete liver assessment (life style questionnaires, physical examination, blood tests, liver ultrasound, Fibroscan). Treated patients (including cirrhotics) are seen every 6 months for treatment dispensation, adherence, physical examination, blood tests, Fibroscan and liver ultrasonography for HCC screening. We are working closely with the head of villages and Imam and community health workers. The Gambian and Senegalese patient association are also strong collaborators of our study.